Pressemitteilungen zu dem Thema vitality biopharma


Unterkategorien

PresseMitteilungen zu dem Schlagwort vitality biopharma


Vitality Biopharma Completes Pivotal GMP Manufacturing Agreements for Cannabinoid Pharmaceuticals

LOS ANGELES, CA -- (Marketwired) -- 11/01/17 -- (OTCQB: VBIO) ("Vitality Biopharma," "Vitality," or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced completion of pivotal manufacturing agreements that enable the production of clinical-grade cannabinoid pharmaceuticals at its R&D facili ...


01.11.2017

Vitality Biopharma Announces Positive Results for Multiple Cannabinoid Drug Formulations in Treatment of IBD

LOS ANGELES, CA -- (Marketwired) -- 10/19/17 -- (OTCQB: VBIO) ("Vitality" or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced additional positive preclinical efficacy results for the treatment of colitis.Vitality Biopharma has developed a new class of cannabinoid prodrugs, known as cannabosides, wh ...


19.10.2017

Vitality Biopharma Announces Publication of International PCT Patent Filing for Cannabinoid Pharmaceuticals

LOS ANGELES, CA -- (Marketwired) -- 10/16/17 -- (OTCQB: VBIO) ("Vitality" or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the publication of an international PCT patent application that covers a new class of cannabinoid pharmaceuticals.The publication of the international patent filing is the fi ...


16.10.2017

Vitality Biopharma Achieves Cannabinoid Pharmaceutical Biosynthesis Breakthrough

LOS ANGELES, CA -- (Marketwired) -- 10/04/17 -- (OTCQB: VBIO) ("Vitality Biopharma", "Vitality", or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the achievement of a biosynthesis breakthrough.Vitality has developed a proprietary biosynthesis technology that can modify cannabinoids in o ...


04.10.2017

Vitality Biopharma Receives Updated SeeThruEquity Price Target of $2.40

LOS ANGELES, CA -- (Marketwired) -- 09/27/17 -- (OTCQB: VBIO) ("Vitality", "Vitality Biopharma", or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to advise that SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, ...


27.09.2017

Vitality Biopharma to Present at The MoneyShow San Francisco Conference

LOS ANGELES, CA -- (Marketwired) -- 08/23/17 -- (OTCQB: VBIO) ("Vitality", "Vitality Biopharma", or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to provide a presentation and participate in a cannabis industry panel session at the MoneyShow San Francisco investment conference.Company CEO Ro ...


23.08.2017

Vitality Biopharma Closes $1 Million Private Placement

LOS ANGELES, CA -- (Marketwired) -- 08/02/17 -- (OTCQB: VBIO) ("Vitality", "Vitality Biopharma", or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to advise that on July 28, 2017, the Company closed on a $1 million private placement.As previously described on the Company''s Current ...


02.08.2017

Vitality Biopharma Releases Positive Results for Treatment of Inflammatory Bowel Disease

LOS ANGELES, CA -- (Marketwired) -- 07/19/17 -- (OTCQB: VBIO) ("Vitality" or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced positive preclinical efficacy results for its gut-targeted cannabosides in the treatment of colitis.Vitality Biopharma has developed a new class of cannabinoid prodrugs, know ...


19.07.2017

Vitality Biopharma Advisor to Present Pediatric IBD Case Study at ICRS2017 in Montreal

LOS ANGELES, CA -- (Marketwired) -- 06/21/17 -- (OTCQB: VBIO) ("Vitality Biopharma," "Vitality", or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, announced today that Company Advisor Dr. Natasha Ryz will be presenting at an international research symposium in Montréal, Canada.Dr. Ryz will provide a po ...


21.06.2017

Vitality Biopharma to Present at the 7th Annual LD Micro Invitational

LOS ANGELES, CA -- (Marketwired) -- 05/30/17 -- (OTCQB: VBIO) ("Vitality Biopharma", "Vitality", or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it will be presenting at the 7th Annual LD Micro Invitational in Los Angeles.The corporate presentation is on Tuesday, June 6th at 9:00 ...


30.05.2017

Vitality Biopharma Adds Key Clinical Advisors in Gastroenterology

LOS ANGELES, CA -- (Marketwired) -- 05/03/17 -- (OTCQB: VBIO) ("Vitality Biopharma," "Vitality", or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to announce and welcomes the appointments of Dr. Douglas A. Drossman and Dr. Mark Gerich as clinical advisors with expertise in gastroenterology a ...


03.05.2017

Vitality Biopharma Releases Clinical Report of Cannabinoid Therapy for Pediatric IBD

LOS ANGELES, CA -- (Marketwired) -- 04/20/17 -- (OTCQB: VBIO) ("Vitality Biopharma", "Vitality", or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the release of one of the first clinical reports detailing the ability of cannabinoid therapy to induce remission in a pediatric inflammatory ...


20.04.2017

Vitality Biopharma Appoints Pharma Industry Veteran to Advance Cannabosides Regulatory Development

LOS ANGELES, CA -- (Marketwired) -- 04/12/17 -- (OTCQB: VBIO) ("Vitality" or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the appointment of Tracy Rockney, J.D., Co-Founder & Chief Operating Officer, OneSource Regulatory, to the position of Senior Regulatory Advisor.Tracy Rockney, J.D. was f ...


12.04.2017

Vitality Biopharma Announces International Patent Filing for Neural Repair Treatments

LOS ANGELES, CA -- (Marketwired) -- 04/05/17 -- (OTCQB: VBIO) ("Vitality" or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the filing of an international patent application in March 2017 that describes compounds discovered to be effective in a drug screening model of neural repair.The underlying ...


05.04.2017

Vitality Biopharma Announces Positive Results for Colon Cancer

LOS ANGELES, CA -- (Marketwired) -- 03/30/17 -- (OTCQB: VBIO) ("Vitality" or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it has positive results indicating a new use for the Company''s proprietary prodrug cannabinoid delivery platform.Multiple colon cancer cell types were screened ...


30.03.2017

Vitality Biopharma Announces Proprietary THC Pharmaceutical with Greatly Decreased Psychoactivity

LOS ANGELES, CA -- (Marketwired) -- 03/02/17 -- (OTCQB: VBIO) ("Vitality" or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it has created a library of proprietary glycosides of THC (delta-9-tetrahydrocannabinol), the main psychoactive chemical found in cannabis or marijuana, which enable targ ...


02.03.2017

Vitality Biopharma to Present at SeeThruEquity 3rd Annual Innovations Investor Conference in Miami

LOS ANGELES, CA -- (Marketwired) -- 02/16/17 -- (OTCQB: VBIO) ("Vitality Biopharma," "Vitality," or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to advise there will be a corporate presentation at the SeeThruEquity 3rd Annual Innovations Investor Conference to be held on Wednesday, February ...


16.02.2017

Vitality Biopharma Publishes Scientific Data on Discovery of Cannabinoid Glycosides

LOS ANGELES, CA -- (Marketwired) -- 02/01/17 -- (OTCQB: VBIO) ("Vitality Biopharma", "Vitality", or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the publication of a scientific manuscript that details internal research efforts including the discovery and production of cannabinoid glyc ...


01.02.2017

Vitality Biopharma to Present at Biotech Showcase 2017

LOS ANGELES, CA -- (Marketwired) -- 01/09/17 -- (OTCQB: VBIO) ("Vitality Biopharma," "Vitality," or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it will present at the Ninth Annual Biotech Showcase 2017 Conference, on January 11, at the Hilton San Francisco Union Square.Company CE ...


09.01.2017

Vitality Biopharma Receives DEA Approval for Cannabinoid Pharma Development Facility

LOS ANGELES, CA -- (Marketwired) -- 12/21/16 -- (OTCQB: VBIO) ("Vitality Biopharma," "Vitality," or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it has received approval from both the U.S. Drug Enforcement Agency (DEA) and the State of California Research Advisory Panel which per ...


21.12.2016

Vitality Biopharma Advances Cannabosides for Treatment of Narcotic Bowel Syndrome

LOS ANGELES, CA -- (Marketwired) -- 11/16/16 -- (OTCQB: VBIO) ("Vitality" or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it is advancing its cannabosides pharmaceuticals for treatment of narcotic bowel syndrome, a severe form of opiate-induced abdominal pain.Every day more than 650,000 op ...


16.11.2016

Vitality Biopharma Announces International Patent Filing for Cannabinoid Pharmaceuticals

LOS ANGELES, CA -- (Marketwired) -- 11/09/16 -- (OTCQB: VBIO) ("Vitality" or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the filing of an international PCT patent application, a milestone in its development of a platform of cannabinoid pharmaceuticals.The Patent Cooperation Treaty (PCT) is an ...


09.11.2016

Vitality Biopharma Reports on Initial Cannabinoid Drug Formulation Studies

LOS ANGELES, CA -- (Marketwired) -- 10/19/16 -- (OTCQB: VBIO) ("Vitality Biopharma," "Vitality," or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced results of recent drug formulation studies that documented substantial modifications to key physiochemical properties of cannabinoids through ...


19.10.2016

Vitality Biopharma Develops Cannabinoid Alternatives to Opiate Prescription Pain Medications

LOS ANGELES, CA -- (Marketwired) -- 09/13/16 -- (OTCQB: VBIO) ("Vitality" or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, wishes to advise that a written by Robert Brooke, Company CEO, sheds new light on key factors in the fight against the increasing epidemic of prescription painkiller related deaths.In his ...


13.09.2016

Vitality Biopharma to Present at Rodman & Renshaw 18th Annual Global Investment Conference

LOS ANGELES, CA -- (Marketwired) -- 09/12/16 -- (OTCQB: VBIO) ("Vitality" or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders announced today that Company CEO, Robert Brooke will be presenting at the Rodman & Renshaw 18th Annual Global Investment Conference to be held September 12, 2016, at the Lotte New York Pa ...


12.09.2016

Vitality Biopharma Announces Expansion of Prodrug Pharmaceutical Portfolio

LOS ANGELES, CA -- (Marketwired) -- 08/24/16 -- (OTCQB: VBIO) ("Vitality" or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced a significant expansion of its glycoside prodrug intellectual property portfolio through the filing of U.S. patent application 62/363,808, which expands upon two previous pat ...


24.08.2016

Vitality Biopharma Begins Trading Under New Stock Symbol "VBIO"

LOS ANGELES, CA -- (Marketwired) -- 08/17/16 -- (OTCQB: VBIO) ("Vitality" or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to announce that effective immediately, its common stock now trades on the over-the-counter market under the symbol "VBIO."Trading of the company''s stock und ...


17.08.2016

Vitality Biopharma Advances Cannabosides for Treatment of Inflammatory Bowel Disease

LOS ANGELES, CA -- (Marketwired) -- 07/27/16 -- (OTCQB: STVFD) ("Vitality" or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced updates to its clinical development plans including the advancement of cannabosides for the treatment of inflammatory bowel disease.Vitality Biopharma has developed a new cl ...


27.07.2016

Vitality Biopharma Name Change and Corporate Actions Receive Shareholder Approval

LOS ANGELES, CA -- (Marketwired) -- 07/19/16 -- (OTCQB: STVF) ("Vitality" or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced shareholder approval and the effective date of a 1-for-10 reverse stock split and a concurrent name change from Stevia First Corp. to Vitality Biopharma, Inc.The reverse sto ...


19.07.2016

Vitality Biopharma to Present at LD Micro and BIO Conferences

LOS ANGELES, CA -- (Marketwired) -- 06/01/16 -- Vitality Biopharma, Inc. (OTCQB: STVF), a company dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that Company CEO Mr. Robert Brooke will be presenting and meeting with investors at the upcoming 2016 LD Micro Invitational and BIO International Conference in June.Vitality Biopharma to present on Tuesd ...


01.06.2016

Launch of Vitality Biopharma for Cannabinoid Prodrug Pharmaceutical Development

LOS ANGELES, CA -- (Marketwired) -- 05/09/16 -- (OTCQB: STVF) (the "Company") is pleased to announce that it is changing its name to Vitality Biopharma, Inc. and that the Company will be dedicated to development of cannabinoid prodrug pharmaceuticals, and unlocking the power of cannabinoids for treatment of serious neurological and inflammatory disorders.In a recent shareholder letter available on the new corporate website at: , the Company''s CEO, Robert Brooke, stated, &q ...


09.05.2016



All members: 9 438
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 71


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.